<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797276</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#201600336</org_study_id>
    <nct_id>NCT01797276</nct_id>
  </id_info>
  <brief_title>Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Open Label</brief_title>
  <acronym>CLA</acronym>
  <official_title>Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Open Label</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open Label access to DCA as continued treatment for congenital lactic acidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who participated in a Phase 3 Randomized Controlled Trial of DCA for treatment of
      Congenital Lactic Acidosis (CLA) are eligible to continue treatment with investigational
      medication DCA at the same dose of 25mg/kg/day. Study participants must travel to the study
      site for bi-annual evaluation by the study investigator. Bi-annual evaluation will include
      an interim medical history review, physical exam, blood collection for DCA trough level, and
      urine pregnancy testing (if indicated).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nerve Conduction Study</measure>
    <time_frame>Bi-annual evaluation</time_frame>
    <description>A standard of care nerve conduction study is completed every 6 months, the report is added to the study record and reviewed by the study investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver function testing</measure>
    <time_frame>Bi-annual evaluation</time_frame>
    <description>Reports from standard liver function blood tests are added to the study record and reviewed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCA trough level</measure>
    <time_frame>Bi-annual evaluation</time_frame>
    <description>Blood sample for DCA trough level is collected prior to the morning dose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Mitochondrial Enzyme Deficiencies</condition>
  <arm_group>
    <arm_group_label>Dichloroacetate Administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are given the drug Dichloroacetate at a dose of 25mg/kg divided in two equal doses each day. They will take this drug for an indefinite period of time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dichloroacetate</intervention_name>
    <description>Subjects are given DCA 25mg/kg in a divided dose twice a day.</description>
    <arm_group_label>Dichloroacetate Administration</arm_group_label>
    <other_name>DCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of congenital lactic acidosis

          -  Participation in Study: #183-1992: Dichloroacetate Treatment of Congenital Lactic
             Acidosis Exclusion Criteria:

          -  Intolerance to DCA
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter W. Stacpoole, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Box 100226</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 24, 2016</lastchanged_date>
  <firstreceived_date>February 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dichloroacetate (DCA)</keyword>
  <keyword>Congenital Lactic Acidosis (CLA)</keyword>
  <keyword>acidosis</keyword>
  <keyword>orphan disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Acidosis, Lactic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
